Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

In this edition of Daily Dose, Dr. Lacy Anderson answers a viewer's question about what discounts are available for weight ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features a real-time scorecard of the Q1 earnings season and freshly updated research reports on ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Plus, salon owners are seeing a massive drawdown in clients coming in for their regular scheduled appointments, citing ...

Less expensive versions of popular weight-loss medications like Wegovy and Zepbound are soon going to be taken off the market ...

A recent study shows consistent users of Eli Lilly's new weight loss drug, Zepbound, have managed to keep the weight off.

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Medicaid plans often put up barriers around newer classes of diabetes medications that offer cardioprotection, according to a ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...